Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Epidemiol. 2010 Aug 9;2:1-3.

Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer.

Author information

1
The Zanvyl Krieger Mind/Brain Institute, Solomon H. Snyder, Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USA.

Abstract

Recently, I put forth the hypothesis that the signaling molecule, norepinephrine (NE), is an etiological factor in a number of types of cancer. In this brief commentary, I summarize evidence that NE plays a role in cancer and describe details involved in testing the hypothesis in humans through epidemiological investigation of existing medical records of persons who have taken pharmaceutical drugs that affect NE. If NE plays an etiological role in cancers of a number of organs, then taking a single pharmaceutical drug (such as clonidine, prazosin, or propranolol) that weakens NE signaling systemically, may simultaneously prevent or treat many different types of cancer, and this may represent a breakthrough in pharmaceutical prevention and possibly treatment of cancer.

KEYWORDS:

acetylcholine; cancer; clonidine; norepinephrine; prazosin; propranolol

PMID:
20865096
PMCID:
PMC2943186
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center